<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926586</url>
  </required_header>
  <id_info>
    <org_study_id>CBF-AML-2016</org_study_id>
    <nct_id>NCT02926586</nct_id>
  </id_info>
  <brief_title>Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML</brief_title>
  <official_title>Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether Fludarabine in combination with cytarabine
      is more effective than high-dose cytarabine in post-remission therapy for patients with
      core-binding factor acute myeloid leukemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with disease recurrence</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Core-Binding Factor</condition>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose cytarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4</description>
    <arm_group_label>Fludarabine</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4</description>
    <arm_group_label>high-dose cytarabine</arm_group_label>
    <other_name>Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and laboratory diagnosis of CBF-AML,including RUNX1-RUNX1T1 and CBF-MYH11
             fusion gene rearrangement by PCR/FISH

          -  In status of complete remission after one to two courses of induction therapy

          -  Total bilirubinic acid ≤ 35μmol/L, AST/ALT&lt;2 times abnormal level, serum creatinine &lt;
             1.5mg/ml

          -  Cardiac function: EF ≥ 50%

          -  Hydroxyurea can be used for patient with white blood cell count ≥ 50*109/L

          -  ECOG (Eastern Cooperative Oncology Group) score: ≤ 2

        Exclusion Criteria:

          -  Relapsed/refractory AML

          -  Serious liver/ kidney dysfunction

          -  Cardiac function level: 2 above

          -  Female in pregnancy or lactation

          -  With serious infection diseases or other diseases

          -  Not obey the principle of clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianmin Song, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of hematology, Shanghai General Hospital, No. 100 Haining Road, Shang</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianmin Song, Doctor</last_name>
    <phone>86-21-63240090-3932</phone>
    <email>shongxm@sjtu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xianmin Song</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianmin Song, Doctor</last_name>
      <phone>86-21-63240090-3932</phone>
      <email>shongxm@sjtu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xianmin Song</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>RUNX1-RUNX1T1</keyword>
  <keyword>CBFβ-MYH11</keyword>
  <keyword>fludarabine</keyword>
  <keyword>cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

